Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients
Conditions: Metastatic Prostate Cancer; Therapy, Directly Observed Interventions: Procedure: Cytoreductive prostatectomy or brachytherapy; Drug: ADT+second-generation antiandrogens ± chemotherapy Sponsors: The First Affiliated Hospital with Nanjing Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform
Conditions: Metastatic Cancer; NSCLC Stage IV; Non-small Cell Lung Cancer Stage IV; Small Cell Lung Cancer Metastatic; Solid Tumor; Clear Cell Renal Cell Carcinoma Metastatic; Urothelial Carcinoma Bladder; Cutaneous Malignant Melanoma; Castration-resistant Prostate Cancer; Prostate Cancer Metastatic; TNBC - Triple-Negative Breast Cancer; Breast Cancer Stage IV; Colon Cancer Stage IV; MSI-H Cancer; Cervical Cancer Stage IV; Endometrial Cancer Stage IV; Mismatch Repair-Deficient Endometrial Endometrioid Adenocarcinoma Interventions: Procedure: Biospecimen Collection; Procedure: Tissue Collection Sponsors: Mayo Clinic Not yet...
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer
Conditions: Prostate Cancer Interventions: Biological: 2141-V11 Antibody Sponsors: Memorial Sloan Kettering Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials
DNA Methylation in Adenocarcinoma of the Prostate: Analysis of Validated Biomarkers in Urine
Conditions: Prostate Adenocarcinoma; Prostate Carcinoma Interventions: Other: Non-Interventional Study Sponsors: Mayo Clinic Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials
Modified Radical Prostatectomy for Prostate Cancer Patients With Enlarged Prostate and Severe Lower Urinary Tract Symptoms: a Single-center, Retrospective Study
Conditions: Prostate Cancer Interventions: Procedure: Two-step Radical Prostatectomy Sponsors: Sun Yat-sen University Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials
Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.
Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC) Interventions: Biological: SL-T10; Biological: GX-I7; Biological: Pembrolizumab Sponsors: SL VAXiGEN Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2024 Category: Research Source Type: clinical trials
Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study
Conditions: Castration-resistant Prostate Cancer Interventions: Drug: Injection, 161Tb-SibuDAB,1GBq; Drug: Injection, 177Lu-PSMA-I&T, 1GBq; Drug: Injection, 161Tb-SibuDAB, Dose Escalation Sponsors: University Hospital, Basel, Switzerland Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
Intratumoral and Systemic Hiltonol ® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance
Conditions: Prostate Cancer Patients on Active Surveillance Interventions: Drug: Poly-ICLC intramuscular (IM) injection; Drug: Poly-ICLC, Intertumoral (IT) injection Sponsors: Ashutosh Kumar Tewari; Oncovir, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
Conditions: Advanced Solid Tumor; HER2-negative Breast Cancer; Metastatic Castration-resistant Prostate Cancer (mCRPC); Pancreatic Cancer; Platinum-resistant Ovarian Cancer (PROC) Interventions: Drug: NUV-1511 Sponsors: Nuvation Bio Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 28, 2024 Category: Research Source Type: clinical trials
Adjuvant Hypofractionated Radiotherapy for Prostate Cancer
Conditions: Prostate Cancer Interventions: Other: Radiotherapy Sponsors: Changhai Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 28, 2024 Category: Research Source Type: clinical trials
INSIDE: Identification of Genomic Screening Pathways in Cancer Patients With DNA Repair Alterations
Conditions: Prostate Cancer Sponsors: Fondazione del Piemonte per l ' Oncologia Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 28, 2024 Category: Research Source Type: clinical trials
Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer
Conditions: Advanced Prostate Cancer Interventions: Diagnostic Test: Ga 68 PSMA-11 PET; Diagnostic Test: 18F-DCFPyL PET; Diagnostic Test: FDG PET Sponsors: University Health Network, Toronto Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 28, 2024 Category: Research Source Type: clinical trials
An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea
Conditions: Non-metastatic Castration-resistant Prostate Cancer; Metastatic Hormone-sensitive Prostate Cancer Interventions: Drug: Darolutamide (Nubeqa, BAY1841788) Sponsors: Bayer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2024 Category: Research Source Type: clinical trials
CyberKnife Ultra-hypofractionated SBRT for Localized PROStatE cancEr
Conditions: Prostate Cancer Interventions: Radiation: CyberKnife ultra-hypofractionated SBRT Sponsors: European Institute of Oncology Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 26, 2024 Category: Research Source Type: clinical trials
177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer
Conditions: Metastatic Prostate Cancer; Castration-resistant Prostate Cancer; Metastatic Castration-resistant Prostate Cancer Interventions: Drug: 177Lu-PSMA-617; Drug: Niraparib abiraterone acetate; Drug: Prednisone Sponsors: Rohan Garje; Janssen Scientific Affairs, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 26, 2024 Category: Research Source Type: clinical trials
